Ian Campbell
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.
Year:
2025
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
Year:
2025
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
Low grade serous carcinoma (LGSOC) is a rare epithelial ovarian cancer with unique molecular characteristics compared to the more common tubo-ovarian high-grade serous ovarian carcinoma. Pivotal clinical trials guiding the management of epithelial ovarian cancer lack sufficient cases of LGSOC for meaningful subgroup analysis, hence overall findings cannot be extrapolated to rarer chemo-resistant subtypes such as LGSOC. Furthermore, there is a need for more effective therapies for the treatment of relapsed disease, as treatment options are limited. To address this, we conducted the largest quantitative high-throughput drug screening effort (n = 3436 compounds) in 12 patient-derived LGSOC cell lines and one normal ovary cell line to identify unexplored therapeutic avenues. Using a combination of high-throughput robotics, high-content imaging and novel data analysis pipelines, our data set identified 60 high and 19 moderate confidence hits which induced cancer cell specific cytotoxicity at the lowest compound dose assessed (0.1 µM). We also revealed a series of known ( mTOR/PI3K/AKT) and novel ( EGFR and MDM2-p53 ) drug classes in which LGSOC cell lines showed demonstrable susceptibility to.
Year:
2024
Background: The effectiveness and cost-effectiveness of genetic testing for hereditary breast and ovarian cancer largely rely on the identification and clinical management of individuals with a pathogenic variant prior to developing cancer. Simulation modelling is commonly utilised to evaluate genetic testing strategies due to its ability to synthesise collections of data and extrapolate over long time periods and large populations. Existing genetic testing simulation models use simplifying assumptions for predictive genetic testing and risk management uptake, which could impact the reliability of their estimates. Our objective was to develop a microsimulation model that accurately reflects current genetic testing and subsequent care in Australia, directly incorporating the dynamic nature of predictive genetic testing within families and adherence to cancer risk management recommendations. Methods: The populatioN gEnEtic testing MOdel (NEEMO) is a population-level microsimulation that incorporates a detailed simulation of individuals linked within five-generation family units. The genetic component includes heritable high- and moderate-risk monogenic gene variants, as well as polygenic risk. Interventions include clinical genetic services, breast screening, and risk-reducing surgery. Model validation is described, and then to illustrate a practical application, NEEMO was used to compare clinical outcomes for four genetic testing scenarios in patients newly diagnosed with breast cancer (BC) and their relatives: (1) no genetic testing, (2) current practice, (3) optimised referral for genetic testing, and (4) genetic testing for all BC. Results: NEEMO accurately estimated genetic testing utilisation according to current practice and associated cancer incidence, pathology, and survival. Predictive testing uptake in first- and second-degree relatives was consistent with known prospective genetic testing data. Optimised genetic referral and expanded testing prevented up to 9.3% of BC and 4.1% of ovarian cancers in relatives of patients with BC. Expanding genetic testing eligibility to all BC patients did not lead to improvement in life-years saved in at-risk relatives compared to optimised referral of patients eligible for testing under current criteria. Conclusions: NEEMO is an adaptable and validated microsimulation model for evaluating genetic testing strategies. It captures the real-world uptake of clinical and predictive genetic testing and recommended cancer risk management, which are important considerations when considering real-world clinical and cost-effectiveness.
Year:
2024
Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.
Year:
2024
Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P
Year:
2024
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
Year:
2024
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples ( 27 ) are shown, as well as alterations in immune genes and CCNE1 . Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS 41 ) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status ( BRCA1 -type HRD; BRCA2 -type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (112)
Charlie Gourley
University of Edinburgh
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Kathleen Claes
Full professor
Ghent University Hospital
Sue K. Park
Professor
Seoul National University College of Medicine
Giuseppe Matullo
-
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Elizabeth Christie
Peter MacCallum Cancer Institute
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Timothy Budden
Lecturer
University of Liverpool
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Nikola A. Bowden
University of Newcastle Australia
Beth Karlan
Vice Chair
University of California, Los Angeles
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Sara González
Institut Català d'Oncologia
FEI CHEN
Assistant Professor
University of Southern California
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Matthew Wakefield
University of Melbourne
Martin Widschwendter
Professor; Director
University of Innsbruck
Martin Köbel
Associate Professor
University of Calgary
Estrid V. Hoegdall
University of Copenhagen
Paul Timpson
Co-Director ACRF (INCITe) Centre
Garvan Institute of Medical Research
Alexandra Martins
INSERM
James D Brenton
University of Cambridge
Julie R Palmer
Boston University School of Medicine
Marc Tischkowitz
Professor and Head of Department
University of Cambridge
Alexander E Volk
-
Jae-Weon Kim
Professor
Seoul National University Hospital
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Cezary Cybulski
Pomeranian Medical University
Lyndal Anderson
University of Western Sydney
Claus Høgdall
Professor in Clinical Gynecologic Oncology
University of Copenhagen
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Mariarosaria Calvello
European Institute of Oncology
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Anthony Gill
University of Sydney
Ioannis Ragoussis
Professor, Head of Genome Sciences
McGill University
Celia Greenwood
McGill University
Linda Cook
Professor
University of Colorado Cancer Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Parham Minoo
Associate Clinical Professor of Pathology
University of Calgary
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Joellen Schilkdraut
Professor
Emory University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Nicholas Hawkins
Emeritus Professor
UNSW Sydney
Setor Amuzu
Memorial Sloan Kettering Cancer Center
Usha Menon
Professor of Gynaecological Oncology
University College London
Gareth Evans
The University of Manchester
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jae-Hoon Kim
Yonsei University College of Medicine
Anna H. Wu
Professor
University of Southern California
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Kylie-Ann Mallitt
Senior Lecturer in Biostatistics
University of Sydney
Dale Garsed
University of Melbourne
Philip Crowe
Professor Surgery
University of New South Wales
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Tomasz Huzarski
Pomeranian Medical University
Byoung-Gie Kim
Sungkyunkwan University School of Medicine
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Dane Cheasley
Senior Research Fellow
University in Western Australia
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Paul Auer
Professor
Medical College of Wisconsin
Jennifer Anne Doherty
Professor
University of Utah
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Corinna Ernst
Hannover Medical School
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Kylie L Gorringe
Group Leader
Peter MacCallum Cancer Institute
Jan Lubiński
Head of Dept
Pomeranian Medical University
Mona El-Bahrawy
Imperial College London
Aleksandra Gentry-Maharaj
University College London
Kathryn Ruddy
Professor
Mayo Clinic
Lidia Feliubadaló
Institut Català d'Oncologia
Koichi Matsuda
University of Tokyo
David G. Huntsman
The University of British Columbia
Janusz Menkiszak
Head of the University Clinic
Pomeranian Medical University
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Paul Cohen
University of Western Australia
Nicholas Boddicker
Research Associate
Mayo Clinic
Aline Talhouk
Assistant Professor
The University of British Columbia
Amanda Toland
Ohio State University
Laura Cortesi
University of Modena and Reggio Emilia
David Lawson Morris
Professor of Surgery
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.